Abnormal Regional Cerebral Blood Flow on 99mTc ECD Brain SPECT in Patients with Primary Sjögren's Syndrome and Normal Findings on Brain Magnetic Resonance Imaging

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2002 Aug 15

PMID 12176800

Citations 5

Authors

C P Chang

Y C Shiau

J J Wang

S T Ho

A Kao

Affiliations

Soon will be listed here.

Abstract

Objective: Technetium-99m ethyl cysteinate dimer (99mTc ECD) single photon emission computed tomography (SPECT) of the brain was used to detect abnormal regional cerebral blood flow (rCBF) in patients with primary Sjögren's syndrome (pSS) and normal findings on brain magnetic resonance imaging (MRI).

Methods: (99m)Tc ECD brain SPECT was performed to detect brain lesions showing hypoperfusion in 32 female patients with pSS and definite neuropsychiatric symptoms or signs. Seventeen female patients with pSS without neuropsychiatric symptoms and signs were included as a control group for comparison. All of the 49 patients with pSS had normal findings on brain MRI.

Results: 99mTc ECD brain SPECT showed brain regions with hypoperfusion in 18 (56.3%) of the 32 patients, and parietal lobes were the most common areas with such lesions. By contrast, 99mTc ECD brain SPECT showed brain regions with hypoperfusion in only three (17.6%) of the 17 patients with pSS without neuropsychiatric symptoms or signs.

Conclusion: This study suggests that 99mTc ECD SPECT is a sensitive tool for detecting regions of hypoperfusion in the brains of patients with pSS and neuropsychiatric symptoms or signs and normal findings on brain MRI. However, a review of the literature showed that the (99m)Tc ECD SPECT findings in patients with pSS were non-specific.

Citing Articles

Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations.

Kocer B, Tezcan M, Batur H, Haznedaroglu S, Goker B, Irkec C Brain Behav. 2016; 6(12):e00586.

PMID: 28032007 PMC: 5167008. DOI: 10.1002/brb3.586.

Intracranial hemodynamic changes in primary Sjögren syndrome: a transcranial Doppler case-control study.

Morreale M, Francia A, Marchione P, Manuppella F, Giacomini P Neurol Sci. 2015; 36(9):1589-95.

PMID: 25868598 DOI: 10.1007/s10072-015-2204-3.

Direct determination of ECD in ECD Kit: a solid sample quantitation method for active pharmaceutical ingredient in drug product.

Chao M, Liu K, Hsia Y, Liao M, Shen L J Biomed Biotechnol. 2011; 2011:196238.

PMID: 21687539 PMC: 3114541. DOI: 10.1155/2011/196238.

Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease.

Piga M, Murru A, Satta L, Serra A, Sias A, Loi G Eur J Nucl Med Mol Imaging. 2008; 35(4):716-24.

PMID: 18180918 DOI: 10.1007/s00259-007-0681-1.

Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up.

Castellino G, Govoni M, Padovan M, Colamussi P, Borrelli M, Trotta F Ann Rheum Dis. 2005; 64(7):1022-7.

PMID: 15640271 PMC: 1755564. DOI: 10.1136/ard.2004.026773.

References

Leveille J, Demonceau G, De Roo M, Rigo P, Taillefer R, Morgan R . Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 2: Biodistribution and brain imaging in humans. J Nucl Med. 1989; 30(11):1902-10. View

Jacobsson L, Axell T, Hansen B, Henricsson V, Larsson A, Lieberkind K . Dry eyes or mouth--an epidemiological study in Swedish adults, with special reference to primary Sjögren's syndrome. J Autoimmun. 1989; 2(4):521-7. DOI: 10.1016/0896-8411(89)90185-6. View

BERMAN J, Kashii S, Trachtman M, BURDE R . Optic neuropathy and central nervous system disease secondary to Sjögren's syndrome in a child. Ophthalmology. 1990; 97(12):1606-9. DOI: 10.1016/s0161-6420(90)32369-2. View

Leveille J, Demonceau G, Walovitch R . Intrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects. J Nucl Med. 1992; 33(4):480-4. View

Manthorpe R, Manthorpe T, Sjoberg S . Magnetic resonance imaging of the brain in patients with primary Sjögren's syndrome. Scand J Rheumatol. 1992; 21(3):148-9. DOI: 10.3109/03009749209095089. View

Vitali C, Bombardieri S, Moutsopoulos H, BALESTRIERI G, Bencivelli W, Bernstein R . Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993; 36(3):340-7. DOI: 10.1002/art.1780360309. View

Matsuda H, Li Y, Higashi S, Sumiya H, Tsuji S, Kinuya K . Comparative SPECT study of stroke using Tc-99m ECD, I-123 IMP, and Tc-99m HMPAO. Clin Nucl Med. 1993; 18(9):754-8. DOI: 10.1097/00003072-199309000-00005. View

Gerraty R, McKelvie P, Byrne E . Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand. 1993; 88(4):309-11. View

Moutsopoulos H, Sarmas J, Talal N . Is central nervous system involvement a systemic manifestation of primary Sjögren's syndrome?. Rheum Dis Clin North Am. 1993; 19(4):909-12. View

10.

Nishimura H, Tachibana H, Makiura N, Okuda B, Sugita M . Corticosteroid-responsive parkinsonism associated with primary Sjögren's syndrome. Clin Neurol Neurosurg. 1994; 96(4):327-31. DOI: 10.1016/0303-8467(94)90124-4. View

11.

Loutfi I, Singh A . Comparison of quantitative methods for brain single photon emission computed tomography analysis in head trauma and stroke. Invest Radiol. 1995; 30(10):588-94. DOI: 10.1097/00004424-199510000-00004. View

12.

van Dyck C, Lin C, Smith E, Wisniewski G, Cellar J, Robinson R . Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease. J Nucl Med. 1996; 37(11):1749-55. View

13.

Koyama M, Kawashima R, Ito H, Ono S, Sato K, Goto R . SPECT imaging of normal subjects with technetium-99m-HMPAO and technetium-99m-ECD. J Nucl Med. 1997; 38(4):587-92. View

14.

Donnemiller E, Heilmann J, Wenning G, Berger W, Decristoforo C, Moncayo R . Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med. 1997; 24(3):320-5. DOI: 10.1007/BF01728771. View

15.

Asenbaum S, Brucke T, Pirker W, Pietrzyk U, Podreka I . Imaging of cerebral blood flow with technetium-99m-HMPAO and technetium-99m-ECD: a comparison. J Nucl Med. 1998; 39(4):613-8. View

16.

Kao C, Lan J, Changlai S, Chieng P . Technetium-99m-HMPAO brain SPECT in Sjögren's syndrome. J Nucl Med. 1998; 39(5):773-7. View

17.

Juni J, Waxman A, Devous Sr M, TIKOFSKY R, Ichise M, van Heertum R . Procedure guideline for brain perfusion SPECT using technetium-99m radiopharmaceuticals. Society of Nuclear Medicine. J Nucl Med. 1998; 39(5):923-6. View

18.

Kao C, Ho Y, Lan J, Changlai S, Liao K, Chieng P . Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum. 1999; 42(1):61-8. DOI: 10.1002/1529-0131(199901)42:1<61::AID-ANR8>3.0.CO;2-9. View

19.

Kao C, Lan J, Changlai S, Liao K, Yen R, Chieng P . The role of FDG-PET, HMPAO-SPET and MRI in the detection of brain involvement in patients with systemic lupus erythematosus. Eur J Nucl Med. 1999; 26(2):129-34. DOI: 10.1007/s002590050368. View

20.

Shen Y, Kao C, Ho Y, Lee J . Regional cerebral blood flow in patients with systemic lupus erythematosus. J Neuroimaging. 1999; 9(3):160-4. DOI: 10.1111/jon199993160. View